PERFORM Publications

Keyword search (4,164 papers available)

Title		Authors	PubMed ID
1	Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)	Chertkow H; Phillips N; Rockwood K; Anderson N; Andrew MK; Bartha R; Beaudoin C; Bélanger N; Bellec P; Belleville S; Bergman H; Best S; Bethell J; Bherer L; Black S; Borrie M; Camicioli R; Carrier J; Cashman N; Chan S; Crowshoe L; Cuello C; Cynader M; Dang-Vu T; Das S; Dixon RA; Ducharme S; Einstein G; Evans AC; Fahnestock M; Feldman H; Ferland G; Finger E; Fisk JD; Fogarty J; Fon E; Gan-Or Z; Gauthier S; Greenwood C; Henri-Bellemare C; Herrmann N; Hogan DB; Hsiung R; Itzhak I; Jacklin K; Lanctôt K; Lim A; MacKenzie I; Masellis M; Maxwell C; McAiney C; McGilton K; McLaurin J; Mihailidis A; Mohades Z; Montero-Odasso M; Morgan D; Naglie G; Nygaard H; O' Connell M; Petersen R; Pilon R; Rajah MN; Rapoport M; Roach P; Robillard JM; Rogaeva E; Rosa-Neto P; Rylett J; Sadavoy J; St George-Hyslop P; Seitz D; Smith E; Stefanovic B; Vedel I; Walker JD; Wellington C; Whitehead V; Wittich W;	39636028 HKAP
2	Comparison of Radiologists and Deep Learning for US Grading of Hepatic Steatosis	Vianna P; Calce SI; Boustros P; Larocque-Rigney C; Patry-Beaudoin L; Luo YH; Aslan E; Marinos J; Alamri TM; Vu KN; Murphy-Lavallée J; Billiard JS; Montagnon E; Li H; Kadoury S; Nguyen BN; Gauthier S; Therien B; Rish I; Belilovsky E; Wolf G; Chassé M; Cloutier G; Tang A;	37787678 ENCS
3	CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment	Brisson M; Brodeur C; Létourneau-Guillon L; Masellis M; Stoessl J; Tamm A; Zukotynski K; Ismail Z; Gauthier S; Rosa-Neto P; Soucy JP;	33532543 PERFORM
4	Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.	Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants	32725777 PERFORM
5	Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment	Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G, Gauthier S, Rosa-Neto P,	32582834 PERFORM
6	Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.	Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P	31530809 PERFORM
7	The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study.	Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsiung GR, Camicioli R, Smith EE, Fogarty J, Lindsay J, Best S, Evans A, Das S, Mohaddes Z, Pilon R, Poirier J, Phillips NA, MacNamara E, Dixon RA, Duchesne S, MacKenzie I, Rylett RJ	31309917 PSYCHOLOGY
8	Brain perfusion during rapid-eye-movement sleep successfully identifies amnestic mild cognitive impairment.	Brayet P, Petit D, Baril AA, Gosselin N, Gagnon JF, Soucy JP, Gauthier S, Kergoat MJ, Carrier J, Rouleau I, Montplaisir J	28522082 PERFORM
9	Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV.	Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA	28894304 PERFORM
10	Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.	Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative	29396637 PERFORM

Title:	Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.
Authors:	Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative
Link:	https://www.ncbi.nlm.nih.gov/pubmed/29396637?dopt=Abstract
DOI:	10.1007/s00259-018-3933-3
Publication:	European journal of nuclear medicine and molecular imaging
Keywords:	Amyloid-PET; Phosphorylated tau; Preclinical Alzheimer'; s disease; [18F]FDG PET;
PMID:	29396637	Category:	Eur J Nucl Med Mol Imaging	Date Added:	2019-04-15
Dept Affiliation:	PERFORM 1 Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, 6875 La Salle Blvd - FBC room 3149, Montreal, QC, H4H 1R3, Canada. 2 Statistical Laboratory, University of Cambridge, Cambridge, UK. 3 Montreal Neurological Institute, Montreal, Canada. 4 PERFORM Centre, Concordia University, Montreal, Canada. 5 Alzheimer's Disease Research Unit, The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Canada. 6 Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, 6875 La Salle Blvd - FBC room 3149, Montreal, QC, H4H 1R3, Canada. pedro.rosa@mcgill.ca. 7 Montreal Neurological Institute, Montreal, Canada. pedro.rosa@mcgill.ca. 8 Alzheimer's Disease Research Unit, The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Canada. pedro.rosa@mcgill.ca. 9 Department of Neurology and Neurosurgery, McGill University, Montreal, Canada. pedro.rosa@mcgill.ca.

Description:

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.

Eur J Nucl Med Mol Imaging. 2018 06;45(6):1021-1030

Authors: Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative

Abstract

PURPOSE: We aimed to determine the amyloid (Aß) and tau biomarker levels associated with imminent Alzheimer's disease (AD) - related metabolic decline in cognitively normal individuals.

METHODS: A threshold analysis was performed in 120 cognitively normal elderly individuals by modelling 2-year declines in brain glucose metabolism measured with [18F]fluorodeoxyglucose ([18F]FDG) as a function of [18F]florbetapir Aß positron emission tomography (PET) and cerebrospinal fluid phosphorylated tau biomarker thresholds. Additionally, using a novel voxel-wise analytical framework, we determined the sample sizes needed to test an estimated 25% drugeffect with 80% of power on changes in FDG uptake over 2 years at every brain voxel.

RESULTS: The combination of [18F]florbetapir standardized uptake value ratios and phosphorylated-tau levels more than one standard deviation higher than their respective thresholds for biomarker abnormality was the best predictor of metabolic decline in individuals with preclinical AD. We also found that a clinical trial using these thresholds would require as few as 100 individuals to test a 25% drug effect on AD-related metabolic decline over 2 years.

CONCLUSIONS: These results highlight the new concept that combined Aß and tau thresholds can predict imminent neurodegeneration as an alternative framework with a high statistical power for testing the effect of disease-modifying therapies on [18F]FDG uptake decline over a typical 2-year clinical trial period in individuals with preclinical AD.

PMID: 29396637 [PubMed - indexed for MEDLINE]

BookR: School of Health Core Facilities Booking

"Gauthier S" Authored Publications:

Search Publications

No results